市場調查報告書
商品編碼
1497579
犬異位性皮膚炎市場:按產品、過敏原、給藥途徑、分銷管道和最終用戶 - 全球預測 2024-2030Canine Atopic Dermatitis Market by Product (Antihistamines, Glucocorticoids, Immunosuppressants), Allergen (Dander, Microorganisms, Mites), Route of Administration, Distribution Channel, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
犬異位性皮膚炎市場規模預計到2023年為15.7億美元,2024年達到16.9億美元,預計到2030年將達到27.6億美元,複合年成長率為8.40%。
犬異位性皮膚炎(CAD)是犬類的一種慢性搔癢性發炎皮膚病,由異常的免疫反應或對環境過敏原的先天傾向所引起。由於生活方式的改變以及寵物健康管理意識的提高,養狗人數不斷增加,目前世界各地都在進行CAD治療。近年來,診斷技術的進步導致了這種慢性疾病的有效治療方法的建立。然而,與診斷和長期管理相關的高成本可能成為飼主的障礙,限制了新療法和療法的引入。在犬異位性皮膚炎市場中,監管障礙可能會阻礙新療法的開發和批准。為了確保各種 CAD 治療方法的商業化,公司正在進行創新研究,提供具有成本效益的治療方法,同時確保了解不斷變化的法規。次世代定序(NGS)等新興技術正在幫助識別導致犬異位性皮膚炎易感性和治療反應的遺傳因素,為個人化治療方法提供有價值的資訊。
主要市場統計 | |
---|---|
基準年[2023] | 15.7億美元 |
預測年份 [2024] | 16.9億美元 |
預測年份 [2030] | 27.6億美元 |
複合年成長率(%) | 8.40% |
區域洞察
由於獸藥市場的顯著開拓以及老牌公司為提供新一代治療方法而不斷進行的研究工作,美洲的 CAD 市場正在不斷發展。在美國和加拿大,越來越多的飼主開始意識到 CAD 對寵物生活品質的影響,該地區對有效治療的需求正在迅速增加。在亞洲國家,尤其是在都市化地區,CAD 的盛行率正在顯著增加。然而,獸醫皮膚病學認知度低和市場結構分散給企業擴張到該地區帶來了挑戰。儘管大型跨國公司在亞洲開展業務,但它們必須與提供經濟高效的 CAD 治療選擇的中小型本地製造商競爭。歐洲市場是一個成熟的獸醫皮膚病市場,其特點是老字型大小企業提供專門的診斷工具和治療解決方案來管理 CAD。大型製藥企業之間的合作正在開發一種突破性的單株抗體療法,以減輕與異位性皮膚炎相關的搔癢。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在犬異位性皮膚炎市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對犬異位性皮膚炎市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對犬異位性皮膚炎市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[190 Pages Report] The Canine Atopic Dermatitis Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.69 billion in 2024, at a CAGR 8.40% to reach USD 2.76 billion by 2030.
Canine atopic dermatitis (CAD) is a chronic, pruritic inflammatory skin condition in dogs due to an inherited predisposition to aberrant immune responses and environmental allergens. Increasing dog ownership rates with changing lifestyles and greater awareness about pet healthcare have led to the adoption of CAD treatments worldwide. Recent years have observed advancements in diagnostic techniques, enabling effective treatment solutions for this chronic condition. However, high costs associated with diagnostics and long-term management can also be a barrier for pet owners, limiting the adoption of new treatments and therapies. Regulatory hurdles can impede the development and approval of novel therapeutics in the canine atopic dermatitis market. Companies are working on innovative research to offer cost-effective treatments while ensuring knowledge of the changing regulations to ensure the commercialization of diverse CAD treatments. Emerging technologies such as next-generation sequencing (NGS) could help identify genetic factors contributing to canine atopic dermatitis susceptibility or treatment response, providing valuable information for personalized therapy approaches.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.57 billion |
Estimated Year [2024] | USD 1.69 billion |
Forecast Year [2030] | USD 2.76 billion |
CAGR (%) | 8.40% |
Regional Insights
The Americas CAD market is advancing, driven by huge developments in veterinary medicine and ongoing research activities by established companies to offer new-generation treatments. With an increasing number of pet owners becoming aware of CAD's impact on their pets' quality of life in the U.S. and Canada, demand for effective treatments has surged in the region. The prevalence of CAD is significantly rising across Asian countries, particularly in urbanized regions. However, limited awareness about veterinary dermatology and fragmented market structures present challenges to companies catering to this region. Major global players have established a presence in Asia; however they need to contend with smaller local manufacturers that offer cost-effective alternatives for CAD treatments. The European market presents a mature landscape for veterinary dermatology, characterized by well-established companies offering specialized diagnostic tools and therapeutic solutions for managing CAD. Partnerships between leading pharmaceutical firms have led to the development of innovative monoclonal antibody therapies, which offer targeted relief from pruritus associated with atopic dermatitis.
Market Insights
The market dynamics represent an ever-changing landscape of the Canine Atopic Dermatitis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Canine Atopic Dermatitis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Canine Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Zoetis Opens New State-of-the-Art Facility in Lincoln, NE, USA
Zoetis conducted the opening of its state-of-the-art mAbs expansion facility in Lincoln, Nebraska, and the facility comprises manufacturing, testing, and support buildings, employing a dedicated workforce of nearly 950 employees who work around the clock year-round. The facility is responsible for the production of animal health biologics, biopharmaceuticals, and pharmaceutical products tailoring to meet the specific needs of animals. [Published On: 2023-08-09]
Zoetis Announces FDA Approval of Apoquel Chewable (oclacitinib chewable tablet) for Control of Pruritus Associated With Allergic Dermatitis and Control of Atopic Dermatitis in Dogs
Zoetis Inc. announced that the FDA approved Apoquel chewable tablet for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and above. This chewable treatment is the first of its kind in the U.S., offering comparable efficacy to the original Apoquel (oclacitinib tablet). [Published On: 2023-06-13]
ILC Therapeutics entered into a strategic R&D partnership with Dechra Pharmaceuticals
UK-based biotech company ILC Therapeutics announced a research and development partnership with Dechra Pharmaceuticals. The collaboration aims to develop ILC's Caniferon product to treat canine atopic dermatitis. This collaboration contributes to their existing pipeline and may lead to a full development program and can enable the effective development of an effective treatment for canine atopic dermatitis. [Published On: 2023-05-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Canine Atopic Dermatitis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Canine Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, AbbVie, Inc., Agrolabo SpA, Bimeda, Inc., Bioceltix JSC, Bioiberica S.A.U., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Deep Marine Collagen, Elanco Animal Health Incorporated, Farnam Companies, Inc., IDEXX Laboratories, Inc., Incyte Corporation, Kemin Industries, Inc., LEO Pharma A/S, Merck & Co. Inc., Natural Dog Company, Nextmune, Nippon Zenyaku Kogyo Co., Ltd., Novartis AG, Ourofino Animal Health, Pfizer Inc, Phibro Animal Health Corporation, Regeneron Pharmaceuticals, Inc, Saiba Animal Health AG, Toray Industries Inc., Vetoquinol S.A., Virbac Corporation, Zinpro Corporation, Zoetis Inc., and Zymox by Pet King Brands LLC.
Market Segmentation & Coverage